Biography and Research Information
OverviewAI-generated summary
Nadia Darwish's research investigates the gut microbiome, particularly in broiler chickens, and its relationship with health and development. Her work has explored how factors such as primer choice for 16S ribosomal RNA analysis and the selection of microbiota databases can impact microbiome studies in chicken ceca. Further research has examined the effects of delayed feed access post-hatch on the gastrointestinal tract microbiota maturation in these birds, and has also delved into the temporal dynamics of the chicken mycobiome. In parallel, Darwish has conducted clinical trials investigating therapeutic vaccines for cervical intraepithelial neoplasia (CIN2/3) and the recurrence of head and neck cancer, focusing on peptide-based human papillomavirus (HPV) vaccines and their immune responses.
Metrics
- h-index: 4
- Publications: 8
- Citations: 106
Selected Publications
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
-
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
-
Temporal dynamics of the chicken mycobiome (2022)
Collaboration Network
Top Collaborators
Monika Proszkowiec‐Weglarz
Agricultural Research Service (US)
4 shared publications
- Choice of 16S ribosomal RNA primers affects the microbiome analysis in chicken ceca
- Research Note: Choice of microbiota database affects data analysis and interpretation in chicken cecal microbiota
- Delayed access to feed early post-hatch affects the development and maturation of gastrointestinal tract microbiota in broiler chickens
- Temporal dynamics of the chicken mycobiome
Teresa Evans
University of Arkansas for Medical Sciences
4 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Jasmine Crane
University of Arkansas for Medical Sciences
4 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Intawat Nookaew
University of Arkansas for Medical Sciences
4 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
David W. Ussery
University of Arkansas for Medical Sciences
4 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Jonathan Shao
United States Department of Agriculture (US)
3 shared publications
- Choice of 16S ribosomal RNA primers affects the microbiome analysis in chicken ceca
- Research Note: Choice of microbiota database affects data analysis and interpretation in chicken cecal microbiota
- Delayed access to feed early post-hatch affects the development and maturation of gastrointestinal tract microbiota in broiler chickens
Lori L. Schreier
Agricultural Research Service (US)
3 shared publications
- Choice of 16S ribosomal RNA primers affects the microbiome analysis in chicken ceca
- Delayed access to feed early post-hatch affects the development and maturation of gastrointestinal tract microbiota in broiler chickens
- Temporal dynamics of the chicken mycobiome
Mayumi Nakagawa
University of Arkansas for Medical Sciences
3 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Hannah Coleman
University of Arkansas for Medical Sciences
3 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Jennifer L. Faulkner
Winthrop Rockefeller Foundation
3 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Yong‐Chen Lu
University of Arkansas for Medical Sciences
3 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Takeo Shibata
University of Arkansas for Medical Sciences
3 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
William W. Greenfield
University of Arkansas for Medical Sciences
3 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Keanna Marsh
University of Arkansas for Medical Sciences
3 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Philip M. Campos
Agricultural Research Service (US)
2 shared publications
- Research Note: Choice of microbiota database affects data analysis and interpretation in chicken cecal microbiota
- Delayed access to feed early post-hatch affects the development and maturation of gastrointestinal tract microbiota in broiler chickens
Similar Researchers
Based on overlapping research topics
Michael Scott Robeson
University of Arkansas for Medical Sciences
Gut microbiota and health
Cervical Cancer and HPV Research
Cancer Treatment and Pharmacology
Michael S. Robeson
University of Arkansas for Medical Sciences
Gut microbiota and health
Microbial Community Ecology and Physiology
Cancer Treatment and Pharmacology
Jiangchao Zhao
University of Arkansas at Fayetteville
Gut microbiota and health
Livestock and Poultry Management
Microbial Community Ecology and Physiology
Rusch NJ
University of Arkansas for Medical Sciences
Gut microbiota and health
Microbial Community Ecology and Physiology
Immune Response and Inflammation
Anne-Karina Perl
University of Arkansas for Medical Sciences
Gut microbiota and health
Microbial Community Ecology and Physiology
Bioinformatics and Genomic Networks
Sabrina May
Arkansas Agricultural Experiment Station
Gut microbiota and health
Livestock and Poultry Management
Microbial Community Ecology and Physiology